✦ LIBER ✦

Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of Nɛ-carboxymethyl lysine

✍ Scribed by Toshihide Kawai; Izumi Takei; Mikiya Tokui; Osamu Funae; Kazunori Miyamoto; Mitsuhisa Tabata; Takumi Hirata; Takao Saruta; Akira Shimada; Hiroshi Itoh

Book ID: 113699828
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 434 KB
Volume: 24
Category: Article
ISSN: 1056-8727
DOI: 10.1016/j.jdiacomp.2008.10.005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of 24 weeks of treatment with epa

Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus

✍ Kenzo Uchida; Toshikazu Kigoshi; Shigeru Nakano; Takashi Ishii; Mitsutaka Kitaza 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 475 KB

Long-term effect of epalrestat, an aldos

Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients

✍ Kaoru Iso; Hisaya Tada; Koji Kuboki; Toshiki Inokuchi 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 114 KB

Effect of long-term treatment with a new

Effect of long-term treatment with a new aldose reductase inhibitor, (2S,4S)-6-fluoro-2′,5′-dioxospiro-[chroman-4,4′-imidazolidine]-2-carboxamide (SNK-860), on peripheral neuropathy in streptozotocin-induced diabetic rats

✍ Noriaki Kato; Kuniharu Mizuno; Akira Matsubara; Kazumasa Nakano; Masayasu Kurono 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 725 KB